Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Novaliq’s NovaTears+Omega-3 represents the first-in-class omega-3-containing eye drop for evaporative dry eye
  2. Varubi IV’s second-try FDA approval provides CINV patients with a new option
  3. The future of orphan drugs in Europe
  4. Innovative trial design: where regulators and payers divide
  5. Ignyta’s Entrectinib is a game-changer for NTRK/ROS1/ALK fusion-positive solid tumors

Latest Content

Prevalence of POAG in Japan Dwarfed by Other Markets

The total prevalence of primary open-angle glaucoma (POAG) is substantially lower in Japan when compared with other markets. In most of the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), the age-standardized prevalence of POAG is at least 1.29% in men 40 years and older and 1.39% in women 40 years and older. However, the age-standardized prevalence of POAG in this age group in Japan is 0.27% in men and 0.15% in women. Figure 1 shows the age-standardized total prevalence of POAG in men and women ages 40 years and older in the 7MM in 2016.

Diagnosed Prevalent Cases of Chronic Kidney Disease Set to Increase Globally

The burden of chronic kidney disease (CKD) in the seven major markets (7MM: US, 5EU [France, Germany, Italy, Spain, UK], and Japan) is expected to grow between 2016 and 2026. GlobalData epidemiologists forecast an increase in the number of diagnosed prevalent cases of CKD, most notably in the 5EU and the US. Figure 1 presents the expected changes in the 7MM from 2016 to 2026.

China’s Growth in Partnership Deals with Pipeline Drugs

Partnership deals that involve drugs in pipeline stage have shown a gradual increase of 8% for the US over the last 5 years. The US still remains to dominate the market, however partnership deals with drugs in pipeline stage for China has also shown a significant increase of 5% from 2013 to 2017.

Syndros, the First FDA-Approved Liquid Dronabinol, Launched After Long Journey

Insys Therapeutics commercially launched Syndros (dronabinol oral solution) on July 31, 2017, becoming the first marketed, FDA-approved liquid dronabinol. The agent was FDA-approved in July 2016 for chemotherapy-induced nausea and vomiting (CINV) patients who have not responded to conventional antiemetic therapies, and for treating anorexia associated with weight loss in acquired immune deficiency syndrome (AIDS) patients.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top